Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00513175
Status:
COMPLETED
Last Update Posted:
2012-11-09
First Post:
2007-08-07
Brief Title:
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies Renal Cell Carcinoma and Aplastic Anemia
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies Renal Cell Carcinoma and Aplastic Anemia
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to examine transplant related mortality TRM at 100 days 30 A TRM of 50 is considered unacceptable This study also seeks a TRM at 12 months that is 50 engraftment 90 defined as donor cells 80 at 6 months and 1 year overall survival 50
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None